首页> 美国卫生研究院文献>Advanced Pharmaceutical Bulletin >Construction and Development of a Cardiac Tissue-Specific and Hypoxia-Inducible Expression Vector
【2h】

Construction and Development of a Cardiac Tissue-Specific and Hypoxia-Inducible Expression Vector

机译:心脏组织特异性低氧诱导表达载体的构建与开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose: Cardiovascular gene therapy is a sophisticated approach, thanks to the safety of vectors, stable transgene expression, delivery method, and different layers of the heart. To date, numerous expression vectors have been introduced in biotechnology and biopharmacy industries in relation to genetic manipulation. Despite the rapid growth of these modalities, they must be intelligently designed, addressing the cardiac-specific transgene expression and less side effects. Herein, we conducted a pilot project aiming to design a cardiac-specific hypoxia-inducible expression cassette.>Methods: We explored a new approach to design an expression cassette containing cardiac specific enhancer, hypoxia response elements (HRE), cardiac specific promoter, internal ribosome entry site (IRES), and beta globin poly A sequence to elicit specific and inducible expression of the gene of interest. Enhanced green fluorescent protein (eGFP) was sub-cloned by BglII and NotI into the cassette. The specificity and inducible expression of the cassette was determined in both mouse myoblast C2C12 and mammary glandular tumor 4T1 as ‘twin’ cells. eGFP expression was evaluated by immunofluorescence microscope and flow cytometry at 520 nm emission peak.>Results: Our data revealed that the designed expression cassette provided tissue specific and hypoxia inducible (O2<1%) transgene expression.>Conclusion: It is suggested that cardiac-specific enhancer combined with cardiac-specific promoter are efficient for myoblast specific gene expression. As well, this is for the first time that HRE are derived from three well known hypoxia-regulated promoters. Therefore, there is no longer need to overlap PCR process for one repeated sequence just in one promoter.
机译:>目的:由于载体的安全性,稳定的转基因表达,递送方法和心脏的不同层次,心血管基因治疗是一种复杂的方法。迄今为止,与基因操作有关的许多表达载体已被引入生物技术和生物制药行业。尽管这些方法迅速发展,但必须对它们进行智能设计,以解决心脏特异性转基因表达和较少的副作用。本文中,我们进行了一个旨在设计心脏特异性缺氧诱导表达盒的试验项目。>方法:我们探索了一种设计包含心脏特异性增强剂,缺氧反应元件(HRE)的表达盒的新方法。 ,心脏特异性启动子,内部核糖体进入位点(IRES)和β珠蛋白poly A序列可引起目标基因的特异性和可诱导表达。增强的绿色荧光蛋白(eGFP)被BglII和NotI亚克隆到表达盒中。在小鼠成肌细胞C2C12和乳腺腺瘤4T1中,作为“双胞胎”细胞都确定了该盒的特异性和诱导表达。通过免疫荧光显微镜和流式细胞仪在520 nm发射峰处评估eGFP的表达。>结果:我们的数据表明,设计的表达盒提供了组织特异性和缺氧诱导(O2 <1%)的转基因表达。 >结论:建议将心脏特异性增强子与心脏特异性启动子结合使用对于成肌细胞特异性基因表达是有效的。同样,这也是HRE首次来自三个众所周知的缺氧调节启动子。因此,不再需要仅在一个启动子中针对一个重复序列进行重叠PCR过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号